REDUCED SEVERE
EXACERBATIONS BY UP TO 81%

BASELINE BLOOD EOS ≥300 CELLS/µL

Significant reductions in severe exacerbations when added to SOC1,a

Severe exacerbations through Week 24 (secondary endpoint)
BASELINE BLOOD EOS ≥300 CELLS/μLTrial 1

SOC, standard of care.


Significant reductions in severe exacerbations when added to SOC1,2,a

Severe exacerbations through Week 52 (secondary endpoint)
BASELINE BLOOD EOS ≥150 CELLS/μLTrial 2

Consistently prevented severe exacerbations in patients with no minimum biomarker requirement when added to SOC1,b,c

Severe exacerbations through Week 52 (primary endpoint)
NO BIOMARKER REQUIREMENT (ITT POPULATION)Trial 2

No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood eosinophils <150 cells/µL taking DUPIXENT 200 mg or 300 mg + SOC and in the ≥150 to <300 cells/µL eosinophil subgroup treated with DUPIXENT 200 mg + SOC vs matching placebo + SOC.1

  • a Severe exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or emergency department visit due to asthma that required systemic corticosteroids.1
  • b ITT population was unrestricted by minimum baseline eosinophils or other Type 2 biomarkers (eg, FeNO or IgE).3
  • c For inclusion in the study, all patients were required to have had ≥1 severe asthma exacerbation in the prior year. Placebo-treated patients with greater numbers of prior exacerbations had greater numbers of exacerbations during the treatment period. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or asthma-related hospitalization or emergency department visit requiring systemic corticosteroids between the first dose and last dose plus 14 days. Subjects with baseline blood eosinophil levels >1500 cells/µL (<1.3%) were excluded.1,4

ITT, intention-to-treat.

See patient types with increased exacerbations appropriate for DUPIXENT

VIEW PATIENTS

References:

  1. DUPIXENT Prescribing Information.
  2. Data on file, Sanofi US. QUEST CSR, 2017.
  3. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
  4. Ford L, Corren J, Kuna P, et al. Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients across prior historical exacerbation subgroups in the phase 3 LIBERTY ASTHMA QUEST study [EAACI abstract 0854]. Allergy. 2018;73(S105):464-465.